Sugi Predict

Sugi Predict / Compounds / SCHEMBL7203265

SCHEMBL7203265

SCHEMBL7203265

CCc1ccc(F)c(N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ TP53 P04637 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TAAR1 Q96RJ0 1/20 0.43
▸ NOS3 P29474 1/20 0.42
▸ NOS1 P29475 1/20 0.42
▸ NOS2 P35228 1/20 0.42
▸ TRPA1 O75762 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2A6 P11509 1/20 0.40
▸ PARP1 P09874 2/20 0.39
▸ SLC6A2 P23975 2/20 0.38
▸ SLC6A4 P31645 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ GAA P10253 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ HTR1D P28221 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29739227 1.00 NPC1 (0.46) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL1068301 0.83 NPC1 (0.59) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL5550176 0.82 ALDH1A1 (0.50) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL13674754 0.79 HSD17B10 (0.40) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL8281240 0.79 LOXL2 (0.48) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL29467998 0.79 LOXL2 (0.48) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL841623 0.78 NOS3 (0.46) NPC1RAB9ASMN1; SMN2TP53TAAR1
SCHEMBL126441 0.78 TRPA1 (0.46) NPC1RAB9ASMN1; SMN2TP53TAAR1
SCHEMBL30361149 0.78 NOS3 (0.46) NPC1RAB9ASMN1; SMN2TP53TAAR1
SCHEMBL31347497 0.77 TAAR1 (0.54) TP53HSD17B10TAAR1CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 — — US disclosed
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2024-08-08 — — US disclosed
US-20240083869-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2024-03-14 — — US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
CN-117242060-A Isoindolinone compounds 蒙特罗萨医疗公司 2023-12-15 — — CN disclosed
EP-4277901-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 — — EP disclosed
US-20230348418-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2023-11-02 — — US disclosed
WO-2022152821-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-07-21 — — WO disclosed
US-20220106323-A1 SPIROCYCLIC ROR-GAMMA MODULATORS ESCALIER BIOSCIENCES B.V. 2022-04-07 — — US disclosed
US-11242350-B2 Spirocyclic ROR-gamma modulators ESCALIER BIOSCIENCES B.V. (US) 2022-02-08 — — US disclosed
US-20140296233-A1 HETEROARYL COMPOUNDS AND USES THEREOF SANOFI (FR) 2014-10-02 — — US disclosed
WO-2013033070-A1 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — WO disclosed
US-20100056505-A1 Substituted Pyrazalones BIOGEN IDEC MA INC. 2010-03-04 — — US disclosed
EP-0705100-B1 THERAPEUTIC SUBSTITUTED GUANIDINES CENES LTD (GB) 2003-07-30 — — EP disclosed
US-6156741-A Therapeutic substituted guanidines CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-12-05 — — US disclosed
US-6153604-A Therapeutic substituted guanidines CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-11-28 — — US disclosed
US-6147063-A NEUROTOXICITY CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-11-14 — — US disclosed
EP-0705100-A4 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE INC (US) 1996-05-29 — — EP disclosed
EP-0705100-A1 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1996-04-10 — — EP disclosed
WO-1994027591-A1 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1994-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056505-A1 Substituted Pyrazalones ACVR1, ACVRL1, TGFBR1 NPC1 4203/4885RAB9A 2969/4885SMN1; SMN2 4777/4885
US-11242350-B2 Spirocyclic ROR-gamma modulators RORA, RORC, RORB NPC1 523/4885RAB9A 914/4885SMN1; SMN2 2068/4885
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 NPC1 285/4885RAB9A 3175/4885SMN1; SMN2 3197/4885
US-20140296233-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 NPC1 48/4885RAB9A 580/4885SMN1; SMN2 2352/4885
US-20240083869-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 NPC1 285/4885RAB9A 3175/4885SMN1; SMN2 3197/4885
US-20230348418-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 NPC1 269/4885RAB9A 3124/4885SMN1; SMN2 3260/4885
US-11912682-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 NPC1 285/4885RAB9A 3175/4885SMN1; SMN2 3197/4885
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MYC, MYCBP, GSPT1 NPC1 3437/4885RAB9A 1613/4885SMN1; SMN2 3190/4885
US-20220106323-A1 SPIROCYCLIC ROR-GAMMA MODULATORS RORA, RORC, RORB NPC1 523/4885RAB9A 914/4885SMN1; SMN2 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.